Can a targeted pill outsmart a tough lung cancer mutation?
NCT ID NCT05276726
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This trial is testing an oral drug called JAB-21822 in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation along with an STK11 mutation. The study aims to see if the drug is safe, tolerable, and effective in shrinking tumors. Participants must have these specific genetic changes and either be untreated or have had prior standard therapy. The trial is in early phases, so it focuses on safety and preliminary signs of benefit.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- JAB-21822, an oral drug that targets a specific genetic mutation (KRAS G12C) in cancer cells
- What this could lead to
- If successful, this could provide a new treatment option for people with a hard-to-treat form of lung cancer that has specific genetic changes.
- What could go wrong
- This is an early-phase trial, so the drug may not work as hoped or may cause side effects. The results are preliminary and need confirmation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
About 104 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2022
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Pathologically documented, locally-advanced or metastatic NSCLC with KRAS p.G12C mutation identified through molecular testing. 2. STK11 co-mutation and KEAP1 Wild-Type (local confirmation) 3. Treatment naïve or have received at least 1 prior standard therapy for advanced NSCLC 4. ECOG 0-1 Exclusion Criteria: 1. Has CNS metastases or carcinomatous meningitis, except treated CNS metastases with no evidence of radiographic progression or hemorrhage for at least 28 days 2. Any severe and/or uncontrolled medical conditions 3. Active infection requiring systemic treatment within 7 days 4. Therapeutic radiation therapy within 3 weeks of study day 1
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
21 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Research site01
RECRUITINGBeijing, Beijing Municipality, 100101, China
-
Research site010
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, 400000, China
-
Research site011
NOT_YET_RECRUITINGShenzhen, Guangdong, 518000, China
-
Research site012
NOT_YET_RECRUITINGChangsha, Hunan, 410000, China
-
Research site013
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 101100, China
-
Research site014
NOT_YET_RECRUITINGHohhot, Neimenggu, 010000, China
-
Research site015
NOT_YET_RECRUITINGChangchun, Jilin, 130000, China
-
Research site016
NOT_YET_RECRUITINGNanning, Guangxi, 530000, China
-
Research site017
NOT_YET_RECRUITINGShijiazhuang, Hebei, 050000, China
-
Research site018
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150000, China
-
Research site019
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310000, China
-
Research site02
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100089, China
-
Research site020
NOT_YET_RECRUITINGXi’an, Shanxi, 710000, China
-
Research site021
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100032, China
-
Research site03
NOT_YET_RECRUITINGHubei, Wuhan, 430060, China
-
Research site04
NOT_YET_RECRUITINGZhengzhou, Henan, 450000, China
-
Research site05
NOT_YET_RECRUITINGXiamen, Fujian, 361000, China
-
Research site06
NOT_YET_RECRUITINGShenyang, Liaoning, 110000, China
-
Research site07
NOT_YET_RECRUITINGShenyang, Liaoning, 110000, China
-
Research site08
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100010, China
-
Research site09
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100010, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo targets stubborn KRAS lung cancer
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Breath-Tracking sensor aims to sharpen lung cancer scans
- Can PET scan signals predict who beats lung cancer with immunotherapy?
- Two-Drug combo takes aim at Hard-to-Treat lung cancer